Explore the vast range of titles available.

Background and Objectives: Early gastric cancer (EGC) has an excellent prognosis when detected, yet miss rates during endoscopy remain high. Narrow-band imaging (NBI) enhances mucosal and vascular visualization and is increasingly used, but its benefit over white-light imaging (WLI) in high-risk patients is uncertain. This study aimed to compare NBI with WLI for the detection of gastric neoplasia in patients undergoing gastroscopy. Materials and Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs), registered in PROSPERO (CRD42025649908) and reported according to PRISMA 2020 guidelines. PubMed, Scopus, and CENTRAL were searched up to October 2024. Eligible RCTs randomized adults undergoing gastroscopy for cancer surveillance or red-flag symptoms to NBI or WLI. Data extraction and risk of bias assessment were performed independently by two reviewers. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model, and certainty of evidence was graded with GRADE. Results: From 21 records, 3 RCTs comprising 6003 patients were included. NBI did not significantly increase gastric neoplasm detection compared with WLI (2.79% vs. 2.74%; RR = 0.98; 95% CI: 0.66–1.45; I2 = 22%). Focal gastric lesion detection rates (14.73% vs. 15.50%; RR = 1.05; 95% CI: 0.72–1.52; I2 = 87%) and positive predictive value (29.56% vs. 20.56%; RR = 1.29; 95% CI: 0.84–1.99; I2 = 61%) also showed no significant differences. Risk of bias was high for blinding, and overall evidence certainty was low. In practical terms, both NBI and WLI detected gastric cancers at similar rates, indicating that while NBI enhances visualization, it does not increase the likelihood of finding additional cancers in high-risk patients. Conclusions: NBI did not significantly improve gastric neoplasm detection compared with WLI in high-risk patients, though it remains valuable for mucosal and vascular assessment. Larger, multicenter RCTs across diverse populations are required to establish its role in surveillance strategies.

Background: The increasing availability of gastrointestinal (GI) interventions has raised the need to treat luminal defects. Endoscopic suturing (ES) is a minimally invasive technique that is used for a wide range of indications. This retrospective cohort study aimed to evaluate the performance of ES in treating upper GI defects. Materials and Methods: Data from a tertiary centre were collected for patients undergoing ES to treat upper GI defects. The primary outcome was long-term outcomes, defined as the successful sutures deployment. Secondary outcomes included technical success, immediate clinical success (confirmation of closure at the time of the procedure), recurrence, and complications. Descriptive statistics and x2 test were used to calculate the rates of the outcomes and assess any link between independent variables and results. Results: Forty-two procedures were performed on 25 patients between 2018 and 2023. The mean age was 55 (±16.2) years, and 56% were female. The long-term clinical success rate was 69.6% (16/23), the technical success rate was 88.1% (37/42), and the immediate clinical success rate was 91.9% (34/37), with only two (4.8%) adverse events. The overall recurrence rate was 61.8% (21/34). Technical success was higher in the esophagus (92.3%), and stomach (100%) (p = 0.002), and immediate clinical success was more likely in patients with leaks (88.9%) or fistula (95.2%) compared to perforation (50%; p = 0.005). Conclusions: ES demonstrated high rates of technical and immediate clinical success for defect closure in the upper GI tract, with low rates of complications. The benefit is most prominently seen among patients with leaks and fistulas in the stomach and esophagus.

Helicobacter pylori infection consists a high global burden affecting more than 50% of the world’s population. It is implicated, beyond substantiated local gastric pathologies, i.e., peptic ulcers and gastric cancer, in the pathophysiology of several neurodegenerative disorders, mainly by inducing hyperhomocysteinemia-related brain cortical thinning (BCT). BCT has been advocated as a possible biomarker associated with neurodegenerative central nervous system disorders such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and/or glaucoma, termed as “ocular Alzheimer’s disease”. According to the infection hypothesis in relation to neurodegeneration, Helicobacter pylori as non-commensal gut microbiome has been advocated as trigger and/or mediator of neurodegenerative diseases, such as the development of Alzheimer’s disease. Among others, Helicobacter pylori-related inflammatory mediators, defensins, autophagy, vitamin D, dietary factors, role of probiotics, and some pathogenetic considerations including relevant involved genes are discussed within this opinion article. In conclusion, by controlling the impact of Helicobacter pylori-related hyperhomocysteinemia on neurodegenerative disorders might offer benefits, and additional research is warranted to clarify this crucial topic currently representing a major worldwide burden.

ObjectiveDuodenal mucosal ablation (DMA) is a novel endoscopic therapy that aims to selectively and reversibly destroy the abnormal hypertrophied duodenal mucosa in patients with inadequately controlled type 2 diabetes mellitus (T2DM) by improving glycated haemoglobin (HbA1c). We conducted a systematic review and meta-analysis to evaluate the pooled efficacy and safety of DMA across the three currently available technologies.Design/methodWe searched Medline, Cochrane and Scopus databases for studies reporting outcomes on DMA up to June 2024. The primary outcome was mean HbA1c reduction within 6 months post-procedure and the secondary outcome was the pooled rate of serious adverse events (SAEs). Meta-analyses were performed using a random-effects model, with results reported as percentages and 95% confidence intervals (CIs).ResultsEight studies (341 patients) were included, evaluating both thermal (REVITA, RFVA) and non-thermal (ReCET) ablation technologies. In patients with inadequately controlled T2DM, the mean HbA1c reduction at 6 months was −1.13% (95% CI −1.37% to −0.89%; I²=93%, p<0.001). SAEs were uncommon, occurring in 0.0%–14.3% with a pooled rate of 2.0% (95% CI 0.0% to 5.0%; I2=10.2%, p=0.35). Meta-regression, after adjustment for outliers, was unable to fully account for the observed heterogeneity, suggesting the influence of unmeasured confounders such as lifestyle management.ConclusionsDMA offers a consistent glycaemic benefit in inadequately controlled T2DM across multiple technologies, with a favourable and evolving safety profile. While procedural refinements, such as increasing ablation length, may enhance efficacy, these must be addressed in parallel with patient-level factors to minimise variability and optimise treatment outcomes.

Viral hepatitis is one of the main causes leading to hepatocellular carcinoma (HCC). The continued rise in incidence of HCC suggests additional factors following infection may be involved. This review examines recent studies investigating the molecular mechanisms of chronic hepatitis and its association with hepatocarcinogenesis. Hepatitis B virus patients with genotype C display an aggressive disease course leading to HCC more than other genotypes. Furthermore, hepatitis B excretory antigen (HBeAg) seems to be a more sensitive predictive tumor marker exhibiting a six-fold higher relative risk in patients with positive HBsAg and HBeAg than those with HBsAg only. Single or combined mutations of viral genome can predict HCC development in up to 80% of patients. Several mutations in HBx-gene are related with higher HCC incidence. Overexpression of the core protein in HCV leads to hepatocellular lipid accumulation associated with oncogenesis. Reduced number and decreased functionality of natural killer cells in chronic HCV individuals dysregulate their surveillance function in tumor and viral cells resulting in HCC. Furthermore, high T-cell immunoglobulin and mucin 3 levels supress CD8+ T-cells, which lead to immunological dysregulation. Hepatitis D promotes HCC development indirectly via modifications to innate immunity, epigenetic alterations and production of reactive oxygen species with the LHDAg being the most highly associated with HCC development. Summarizing the results, HBV and HCV infection represent the most associated forms of viral hepatitis causing HCC. Further studies are warranted to further improve the prediction of high-risk patients and development of targeted therapeutics preventing the transition from hepatic inflammation–fibrosis to cancer.

Background and Aims: Endoscopic retrograde cholangiopancreatography (ERCP), in surgically altered anatomy (SAA), can be challenging and the optimal technique selection remains debatable. Most common foregut interventions resulting to this burden consist of Billroth II gastrectomy, Whipple surgery and Roux-en-Y anastomoses, including gastric by-pass. This systematic review, with meta-analysis, aimed to compare the rates of successful enteroscope-assisted (EA)-, endosonography-directed transgastric- (EDGE), and laparoscopy-assisted (LA)-ERCP. Methods: A systematic research (Medline) was performed for relative studies, through January 2022. The primary outcome was technical success, defined as approaching the ampulla site. Secondary outcomes included the desired duct cannulation, successful therapeutic manipulations, and complication rates. We performed meta-analyses of pooled data, and subgroup analysis considering the EA-ERCP subtypes (spiral-, double and single balloon-enteroscope). Pooled rates are reported as percentages with 95% Confidence Intervals (95%CIs). Results: Seventy-six studies were included (3569 procedures). Regarding primary outcome, EA-ERCP was the least effective [87.3% (95%CI: 85.3–89.4); I2: 91.0%], whereas EDGE and LA-ERCP succeeded in 97.9% (95%CI: 96.4–99.4; I2: 0%) and 99.1% (95%CI: 98.6–99.7; I2: 0%), respectively. Similarly, duct cannulation and therapeutic success rates were 74.7% (95%CI: 71.3–78.0; I2: 86.9%) and 69.1% (95%CI: 65.3–72.9; I2: 91.8%) after EA-ERCP, 98% (95%CI: 96.5–99.6; I2: 0%) and 97.9% (95%CI: 96.3–99.4) after EDGE, and 98.6% (95%CI: 97.9–99.2; I2: 0%) and 98.5% (95%CI: 97.8–99.2; I2: 0%) after LA-ERCP, respectively. The noticed high heterogeneity in EA-ERCP results probably reflects the larger number of included studies, the different enteroscopy modalities and the variety of surgical interventions. Comparisons revealed the superiority of LA-ERCP and EDGE over EA-ERCP (p ≤ 0.001) for all success-related outcomes, though LA-ERCP and EDGE were comparable (p ≥ 0.43). ERCP with spiral-enteroscope was inferior to balloon-enteroscope, while the type of the balloon-enteroscope did not affect the results. Most adverse events were recorded after LA-ERCP [15.1% (95%CI: 9.40–20.8); I2: 87.1%], and EDGE [13.1% (95%CI: 7.50–18.8); I2: 48.2%], significantly differing from EA-ERCP [5.7% (95%CI: 4.50–6.80); p ≤ 0.04; I2: 64.2%]. Conclusions: LA-ERCP and EDGE were associated with higher technical, cannulation, and therapeutic success compared to EA-ERCP, though accompanied with more adverse events.

Gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) comprise a heterogeneous group of slow growing tumors arising from the neuroendocrine cells of the gastrointestinal (GI) tract. Although they are considered relatively rare, their incidence is rising and it is believed that the more frequent use of endoscopy and imaging studies have at least in part contributed to the increased diagnosis especially of localized neoplasms. The management of these neoplasms should be guided by a multidisciplinary NEN team following appropriate staging investigations. Localized neoplasms of the GI tract may be suitable for endoscopic therapy, while patients with pancreatic NENs, unsuitable for surgery, should be considered for endoscopic ultrasound (EUS)-guided ablation. In this review, we discuss the evidence regarding endoscopic resection of luminal NENs and EUS-guided therapy of pancreatic NENs. The efficacy, safety, and other longer-term outcomes of these techniques are summarized. In conclusion, this review of endoscopic therapies for localized NENs may be a useful guide for NEN clinicians and endoscopists who are considering these therapeutic options for the management of focal GEP NENs.